<DOC>
	<DOCNO>NCT00440414</DOCNO>
	<brief_summary>The second-line treatment advance NSCLC currently prove effective prolong overall survival improve quality life . Both pemetrexed erlotinib approve second-line treatment NSCLC . Erlotinib valuable option treatment advance NSCLC , especially elderly patient , due convenience administration safety profile . The role comprehensive geriatric assessment treatment efficacy tolerance area investigation .</brief_summary>
	<brief_title>Trial Pemetrexed Versus Erlotinib Pretreated Patients With Non Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>This trial compare efficacy pemetrexed versus erlotinib pretreated patient advanced NSCLC .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologically cytologically confirm NonSmallCell Lung Cancer adenocarcinoma Stage IIIB/IV Failure prior chemotherapy Presence twodimensional measurable disease . The measurable disease irradiate Absence irradiate stable central nervous system metastatic disease . Life expectancy 3 month Tissue sample desire genomic study Age â‰¥ 18 year Performance status ( WHO ) &lt; 3 For patient &gt; 65 year old : `` nonfrail '' accord comprehensive geriatric assessment Adequate bone marrow function ( absolute neutrophil count &gt; 1000/mm^3 , platelet count &gt; 100000/mm^3 , hemoglobin &gt; 9gr/mm^3 ) Adequate liver ( bilirubin &lt; 1.5 time upper limit normal SGOT/SGPT &lt; 2 time upper limit normal ) renal function ( creatinine &lt; 2mg/dl ) Presence reliable care giver patient &gt; 65 year old Informed consent . Psychiatric illness social situation would preclude study compliance Other concurrent uncontrolled illness Other invasive malignancy within past 5 year except nonmelanoma skin cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Non-small-cell lung cancer</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Pemetrexed</keyword>
	<keyword>Erlotinib</keyword>
</DOC>